Jazz Pharmaceuticals plc

NASDAQ:JAZZ   4:00:00 PM EDT
121.45
+2.34 (+1.96%)
4:37:23 PM EDT: $120.46 -1.00 (-0.82%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.65B
Current PE95.63
Forward PE 6.58
2yr Forward PE 6.11
See more stats
Estimates Current Quarter
Revenue$1.02 Billion
Adjusted EPS$5.13
See more estimates
10-Day MA$119.37
50-Day MA$126.54
200-Day MA$133.16
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.